Competitive Advantages
- A novel molecule that can inhibit P. falciparum in malaria
- Bypasses drug resistance
- Limited toxicity towards human cells
Summary
USF researchers have developed a novel modified hexapeptide called friomaramide. It inhibits the growth of P. falciparum to a similar degree as the antimalarial drug primaquine, with the added benefit of bypassing growing antimalarial resistance. It is also less toxic to human cells. Friomaramide may prove to be a huge benefit to the millions of people infected with malaria worldwide every year.
Friomaramide Showing Comparable Inhibition of P. falciparum as Prinaquine
Desired Partnerships
- License
- Sponsored Research
- Co-Development